Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (<i>R</i>)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (PF-06821497)Pei‐Pei Kung, Martin P. Edwards, Cody Krivacic et al.|Journal of Medicinal Chemistry|2017Cited by 129
Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2 <i>H</i> )-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) InhibitorsPei‐Pei Kung, Martin P. Edwards, Eugene Rui et al.|Journal of Medicinal Chemistry|2016Cited by 70
Correction to Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2<i>H</i>)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) InhibitorsPei‐Pei Kung, Martin A. Edwards, Eugene Rui et al.|Journal of Medicinal Chemistry|2016Cited by 4
CCDC 1982336: Experimental Crystal Structure DeterminationPei‐Pei Kung, Martin P. Edwards, Patrick Bingham et al.|The Cambridge Structural Database|2020Cited by 0
CCDC 1982338: Experimental Crystal Structure DeterminationPei‐Pei Kung, Martin A. Edwards, Patrick Bingham et al.|The Cambridge Structural Database|2020Cited by 0